Coverage clusters in markets, which accounts for 3 of those 5, with the remainder spread across 2 other categories. Of the tracked stories, 2 of 5 also mention Jensen Huang, the most common co-covered peer. Sentiment skews less negative than the wider beat, at 20% negative against 29% across all 2361 Finance stories in the same window.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about UBS
Coverage clusters in markets, which accounts for 3 of those 5, with the remainder spread across 2 other categories. Of the tracked stories, 2 of 5 also mention Jensen Huang, the most common co-covered peer. Sentiment skews less negative than the wider beat, at 20% negative against 29% across all 2361 Finance stories in the same window. Across a 28-day span, the pace is roughly 1.3 stories per week. At 6.6, the average consequence score sits above the same-window beat average of 6.3. They are less corroborated than the beat average, carrying 2.4 original sources each against 2.6 for the same window. We currently track 5 Finance stories that mention UBS, published between February 26, 2026 and March 25, 2026.
Stories tracked
5
Per week
1.3
Negative
20%
Sources per story
2.4
Computed from the 5 stories linked to this entity, with beat comparisons drawn from all 2361 Finance stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering UBS. Shared-story counts are live from our verified record — not editorial picks.
UBS has significantly lowered its price target for The Campbell's Company (CPB) from $24 to $20, signaling deep caution over the food giant's growth trajectory. The move reflects broader sector headwinds as packaged food companies struggle to balance price hikes with declining consumer volume.
Goldman Sachs has reiterated its bullish $250 price target for Nvidia following the GTC 2026 conference, dismissing bearish concerns about slowing AI demand. Analysts cite increased visibility into hyperscaler spending and the strength of the Blackwell architecture as primary drivers for continued market dominance.
The House Select Committee on China has warned that Beijing is executing a strategic 'playbook' to dominate the global pharmaceutical market, mirroring its previous successes in rare earths and electric vehicles. With Chinese medical revenue projected to reach $2.1 trillion by 2030, US officials are weighing the national security risks of a supply chain heavily dependent on Chinese-made active pharmaceutical ingredients.
UBS has reiterated a strong Buy rating on Nvidia with a $245 price target following a record-breaking fiscal fourth quarter and massive forward guidance. The firm's bullishness stems from accelerating data center demand and the arrival of the 'agentic AI' era, which is driving inventory commitments to unprecedented levels.
UBS has revised its price target for Brookfield Asset Management (BAM) downward to $52 while maintaining a Neutral rating. The adjustment reflects a cautious stance on the alternative asset manager's valuation and growth trajectory in a shifting global interest rate environment.